Peptide Purity Testing: How to Verify Purity From a COA (2026)

Peptide purity testing is the process of reading a batch's Certificate of Analysis (COA) to confirm what is — and isn't — in the vial. To verify purity you read three things: the HPLC chromatogram (a percentage from peak-area math), the mass-spectrometry result (does the molecule match the target?), and — critically — a separate endotoxin test, which HPLC cannot detect. This guide explains each part of peptide purity testing.

Peptide purity verification at a glance

• What a COA reports: purity (HPLC), identity (mass spectrometry), and ideally endotoxin, sterility, and residual-solvent data
• HPLC purity: main-peak area ÷ total peak area, expressed as a percentage; research-grade material is commonly reported as >95–99%
• Identity: mass spectrometry confirms the observed mass matches the peptide's theoretical mass
• The blind spot: HPLC and mass spec cannot detect bacterial endotoxin — a separate test (USP <85> LAL) is required
• Batch-specific: a valid COA matches the exact lot number you received, not a generic "representative" sample
• What it is not: a COA is a quality document, not a safety clearance or an FDA approval

What is a peptide Certificate of Analysis (COA)?

A Certificate of Analysis (COA) is a document — ideally from an independent, accredited laboratory — that reports the measured quality attributes of a specific peptide batch. A complete COA identifies the peptide by name and sequence, lists a unique lot or batch number, and reports analytical results: purity, identity (molecular weight), and, in higher-quality documents, water content, residual solvents, counter-ion content, endotoxin, and sterility.

The key principle is that a COA describes one batch, not a product line in general. Peptides are made by solid-phase synthesis, and each synthesis run produces a slightly different impurity profile. For COA-based verification to mean anything, the lot number on the document must match the lot number on the vial you actually received. A "representative" COA detached from your specific batch verifies nothing about your specific batch.

It is worth stating plainly what a COA is not. It is not an FDA approval, it is not a prescription, and it is not a guarantee of safety in humans. Most research peptides sold in the United States are labeled "research use only" and are not FDA-approved for human use. A COA reports chemistry; it cannot speak to whether a compound is appropriate, dosed correctly, or safe for any individual. Consult your healthcare provider before considering any peptide.

For broader context on selecting suppliers, see our peptide sourcing guide and the peptide vendor scorecard.

How is peptide purity actually measured?

The headline purity number on almost every COA comes from high-performance liquid chromatography (HPLC), typically reversed-phase HPLC. In this method, the dissolved peptide is pushed through a column that separates molecules by how strongly they stick to the column packing. The target peptide and any impurities elute (come out) at different times, producing a chromatogram — a graph of detector signal versus time, with one large peak for the main compound and smaller peaks for impurities.

Purity is then calculated by area normalization: the area under the main peak divided by the total area of all peaks, expressed as a percentage. A report of "98.4% purity by HPLC" means the main peak accounts for 98.4% of the total detected peak area, with the remaining 1.6% attributed to detectable impurities. Reversed-phase HPLC is the primary method used to evaluate purity, identity, content, and stability of synthetic peptide reference standards (McCarthy et al., 2023, Pharmaceutical Research).

Two limitations are important. First, HPLC only "sees" what the detector responds to — usually UV absorbance — so a co-eluting impurity that absorbs poorly, or one hidden under the main peak, may be undercounted. Second, area-percent purity is a relative measure of peptide-related impurities; it is not the same as the absolute content (how many milligrams of actual peptide are in the vial), which requires a quantitative assay against a reference standard.

How does mass spectrometry confirm identity?

HPLC tells you how pure a sample is, but not what the main peak is. A batch could be 99% one substance — and that substance could be the wrong peptide. Mass spectrometry (MS) closes that gap by measuring the molecular weight of the main component and comparing it to the theoretical mass calculated from the amino-acid sequence.

On a COA, you will typically see a "theoretical (calculated) mass" and an "observed (found) mass." When the observed mass matches the theoretical mass within the instrument's expected accuracy, that is evidence the main peak really is the intended peptide and not a synthesis error such as a missing or extra amino acid. Mass spectrometry is one of the orthogonal techniques — alongside NMR and amino-acid analysis — used to confirm the identity of synthetic peptide standards (McCarthy et al., 2023, Pharmaceutical Research).

Together, HPLC plus MS form the minimum credible identity-and-purity package: HPLC quantifies purity, MS confirms identity. A COA reporting only one of the two is incomplete.

Why can a 99% pure peptide still be contaminated?

This is the single most important and least understood point in peptide purity testing: HPLC and mass spectrometry cannot detect bacterial endotoxin. Endotoxins are lipopolysaccharides (LPS) from the outer membrane of Gram-negative bacteria. They are not peptides, so they do not register as a peptide-related impurity on an HPLC chromatogram and do not appear in the peptide's mass spectrum. A batch can be "99% pure by HPLC" and still carry a biologically meaningful endotoxin load.

This is not a theoretical edge case. A systematic screen of commonly used commercial protein and peptide preparations found that many contained detectable LPS, and that this contamination — not the intended molecule — drove much of the observed biological activity; the effect was blocked by the LPS inhibitor polymyxin B in commercial-grade but not pharmaceutical-grade preparations (Weinstein et al., 2008, Glia). Because LPS activates innate immune signaling at picogram quantities, trace contamination invisible to chemistry-based methods can still be biologically significant.

Detecting endotoxin requires a dedicated bacterial endotoxins test (BET) — the Limulus Amebocyte Lysate (LAL) assay described in USP <85>, or a recombinant-Factor-C alternative under USP <86>. A purity-only COA that omits endotoxin testing leaves this risk completely unmeasured. This is a safety-relevant gap: consult your healthcare provider, and treat any preparation lacking endotoxin and sterility data as unverified for that risk.

What else should a thorough COA report?

Beyond HPLC purity, MS identity, and endotoxin, a rigorous COA addresses the by-products of synthesis itself:

• Residual solvents — leftover organic solvents from synthesis and purification, addressed pharmacopeially under USP <467>.
• Counter-ions / residual acids — peptides purified by reversed-phase HPLC are commonly isolated as trifluoroacetic acid (TFA) or acetic acid salts. USP has dedicated chapters for acetic acid in peptides (USP <503>) and trifluoroacetic acid in peptides (USP <503.1>) (McCarthy et al., 2023, Pharmaceutical Research).
• Water content — lyophilized (freeze-dried) peptides retain water; measuring it (USP <921>) is necessary to know the true peptide content (McCarthy et al., 2023, Pharmaceutical Research).
• Net peptide content / assay — the actual milligrams of peptide per vial. Because of water, counter-ions, and impurities, net content is always lower than the gross fill weight. A rigorous "mass balance" approach establishes purity by measuring every detectable impurity class and subtracting from 100% (McCarthy et al., 2023, Pharmaceutical Research).
• Sterility — for any preparation intended for parenteral (injectable) use, sterility (USP <71>) is a separate test from purity.

A COA reporting only a single HPLC percentage is the floor, not the standard. The most informative documents combine chromatography, mass spec, and the contamination-and-content tests above.

How do you spot a fake or low-quality COA?

Use this practical checklist when verifying any peptide purity document:

1. Lot match. Does the batch/lot number on the COA exactly match the vial you received? If not, the document is unverifiable.
2. Independent lab. Was testing performed by a third-party, accredited laboratory (for example, an ISO/IEC 17025-accredited lab), or is it an unsigned in-house printout?
3. Raw data, not just a number. A credible COA shows the actual HPLC chromatogram and mass-spec trace, not only a typed "99%."
4. Both purity and identity. HPLC purity and mass-spec identity should both appear.
5. Contamination testing. Are endotoxin (USP <85>) and, for injectables, sterility (USP <71>) reported — or silently absent?
6. Date and signature. Is the report dated, attributed to a named lab, and signed?
7. Internal consistency. Do the peptide name, sequence, molecular formula, and theoretical mass agree with one another?

If you want to go further, some buyers send a portion of a received batch to an independent testing lab for confirmation. Independent re-testing is the only way to confirm that a vendor-supplied COA actually describes the material in your hand. As always, consult your healthcare provider before using any peptide, and treat sourcing as a safety decision, not just a price decision. For more on supplier evaluation, see the peptide vendor scorecard.

How does FDA regulatory status affect what you can verify?

Purity testing does not change a peptide's legal status, and legal status shapes what documentation is even available. Many popular research peptides are not FDA-approved drugs. Under the federal compounding framework, FDA evaluates bulk drug substances nominated for use in compounding under section 503A, and has placed certain substances it considers to present significant safety risks into a "Category 2," which removes them from the list pharmacies can lawfully compound from while review continues (FDA, Bulk Drug Substances Used in Compounding Under Section 503A).

Several widely discussed peptides — reported to include BPC-157, TB-500/thymosin beta-4, KPV, MOTS-C, Semax, and Epitalon — are scheduled for review by FDA's Pharmacy Compounding Advisory Committee (PCAC) at a meeting on July 23–24, 2026 [VERIFY: exact peptide-by-day split and final agenda, per FDA advisory-committee calendar listing for the July 2026 PCAC meeting]. Even a favorable PCAC recommendation would not immediately make a substance compoundable; FDA must still complete formal notice-and-comment rulemaking (FDA, Pharmacy Compounding Advisory Committee materials).

The practical takeaway: a COA verifies chemistry, not legality. Legal status varies by jurisdiction and is changing in 2026 — consult a lawyer for binding advice, and see our peptide legal status overview for current context.

Frequently asked questions

Q: What does ">99% purity" on a peptide COA actually mean? A: It almost always refers to HPLC area-percent purity: the main peak accounts for over 99% of the total detected peak area, with under 1% attributed to detectable peptide-related impurities. It does not measure endotoxin, sterility, or the absolute milligrams of peptide in the vial, and it depends on the detector "seeing" each impurity. A high HPLC number is necessary but not sufficient for overall quality.

Q: Can HPLC detect bacterial contamination or endotoxin? A: No. Endotoxins (lipopolysaccharides) are not peptides and do not appear on an HPLC chromatogram or in a peptide's mass spectrum. A systematic screen found significant LPS contamination in commercial-grade preparations that passed standard chemical specifications (Weinstein et al., 2008, Glia). Detecting endotoxin requires a separate Limulus Amebocyte Lysate (LAL) assay under USP <85>. Consult your healthcare provider about contamination risk.

Q: What is the difference between HPLC purity and net peptide content? A: HPLC purity is a relative measure — what fraction of detected peptide material is the target. Net peptide content is an absolute measure — how many milligrams of actual peptide are in the vial, after accounting for water, counter-ions (like TFA or acetic acid), and impurities. Net content is always lower than gross fill weight and requires a separate quantitative assay (McCarthy et al., 2023, Pharmaceutical Research).

Q: Why does mass spectrometry appear on a COA if HPLC already shows purity? A: Because HPLC tells you how pure the main component is, but not what it is. Mass spectrometry confirms the observed molecular weight matches the theoretical mass of the intended peptide, catching synthesis errors like a missing or substituted amino acid (McCarthy et al., 2023, Pharmaceutical Research). Purity without identity is incomplete; the two tests answer different questions.

Q: Is a COA the same as FDA approval? A: No. A COA is a private laboratory document describing one batch's chemistry. It is not an FDA approval, not a prescription, and not a clearance for human use. Most research peptides are labeled "research use only" and are not FDA-approved. Legal status is evolving in 2026, including FDA's 503A bulk-substance review and the July 2026 PCAC meeting. Consult a lawyer for legal questions and a healthcare provider for medical ones.

Q: How can I independently verify a vendor's COA? A: Confirm the lot number on the COA matches your vial; check that an independent, accredited lab performed the testing; look for the actual HPLC chromatogram and mass-spec trace rather than a typed number; and confirm endotoxin and sterility data are present for injectables. For full confidence, send a sample of your received batch to a third-party lab for independent re-testing.

Q: What purity percentage is "good enough" for research peptides? A: There is no single universal threshold, and the right answer depends on the application — consult your healthcare provider for anything involving human use. Research-grade material is commonly reported above 95–99% by HPLC, but purity percentage alone is incomplete without identity confirmation, contamination testing, and net-content data. A lower-purity COA with full endotoxin and identity data can be more informative than a bare "99%" with nothing else.

References

1. McCarthy D, Han Y, Carrick K, Schmidt D, Workman W, Matejtschuk P, Duru C, Atouf F. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharmaceutical Research. 2023;40(6):1317–1328. PMID: 36949371. DOI: 10.1007/s11095-023-03493-1. PMC: PMC10338602.
2. Weinstein JR, Swarts S, Bishop C, Hanisch UK, Möller T. Lipopolysaccharide is a frequent and significant contaminant in microglia-activating factors. Glia. 2008;56(1):16–26. PMID: 17910052. DOI: 10.1002/glia.20585.
3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act.
4. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) — Advisory Committee Calendar (July 23–24, 2026 meeting). FDA.gov. https://www.fda.gov/advisory-committees/about-advisory-committees/pharmacy-compounding-advisory-committee.
5. United States Pharmacopeia. General Chapter <85> Bacterial Endotoxins Test (LAL). USP–NF. https://www.usp.org/.